Combined therapy of teicoplanin and caffeic acid phenethyl ester (CAPE) in the treatment of experimental mediastinitis in the rat

Journal of Chemotherapy

Volumn 18, Issue 3, 2006, Pages 268-277

  Aytacoglu, Barlas N ^a   Ersoz, G ^a   Sucu, N ^a   Tamer, L ^a   Coskun, B ^a   Oguz, I ^a   Bayindir, I ^a   Kose, N ^a   Ozeren, M ^a   Dikmengil, M ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

CAPE; Mediastinitis; Teicoplanin

Indexed keywords

CAFFEIC ACID PHENETHYL ESTER; CREATINE; MALONALDEHYDE; MYELOPEROXIDASE; NITRIC OXIDE; SODIUM CHLORIDE; TEICOPLANIN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; CELL INFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; INFECTION RATE; INFLAMMATION; MEDIASTINITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; RAT; TREATMENT OUTCOME; UREA BLOOD LEVEL;

EID: 33746227578     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.3.268     Document Type: Article

References (47)

1. Loop FD, Lytle BW, Cosgrove DM, et al. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. Ann Thorac Surg 1990; 49: 179-186.
2. Farinas MC, Gald PF, Bernai JM, Rabasa JM, Revuelta JM, Gonzalez-Macias J. Supurative mediastinitis after open heart surgery: a case control study covering a seven-year period in Santander, Spain. Clin Infect Dis 1995; 20: 272-279.
3. Ridderstolpe L, Gill H, Granfeldt H, Ahlfeldt H, Rutberg H. Superficial and deep sternal wound complications: incidence, risk factors and mortality. Eur J Cardiothorac Surg 2001; 20: 1168-1175.
4. Combes A, Trouillet JL, Joly-Guilou ML, Chastre J, Gibert C. The impact of methicillin resistance on the outcome of poststernotomy mediastinitis due to Staphylococcus aureus. Clin Infect Dis 2004; 38: 822-829.
5. Fowler VG Jr, Kaye KS, Simel DL, et al. Staphylococcus aureus bacteremia after median sternotomy: clinical utility of blood culture results in the identification of postoperative mediastinitis. Circulation 2003; 108: 73-8.
6. Fischer W. Lipoteichoic acid and lipids in the membrane of staphylococcus aureus. Med Microbiol Immunol 1994; 183: 61-76.
7. Risnes I, Ueland T, Aukrust P, et al. Complement activation and cytokine and chemokines release during mediastinitis. Ann Thorac Surg 2003; 75: 981-985.
8. Lin CH, Hsu RB, Chang SC, Lin FY, Chu SH. Poststernotomy mediastinitis due to methicillin-resistant Staphylococcus aureus endemic in a hospital. Clin Infect Dis 2003; 37: 679-684.
9. Abboud CS, Wey SB, Baltar VT. Risk factors for mediastinitis after cardiac surgery. Ann Thorac Surg 2004; 77: 676-683.
10. Zeitani J, Bertoldo F, Bassano C, et al. Superficial wound dehiscence after median sternotomy: surgical treatment versus secondary wound healing Ann Thora Surg 2004; 77: 672-675.
11. Swenne CL, Lindholm C, Borowiec J, Carlson M. Surgical-site infections within 60 days of coronary artery bypass graft surgery. J Hosp Infect 2004; 57: 14-24.
12. Dodds Ashley ES, Carroll DN, Engemann JJ, et al. Risk factors for mediastinitis due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004; 38: 1555-1560.
13. Campoli-Richards DM, Brogden RN, Faulds D. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1990; 40: 449-486.
14. Lewis P, Garaud JJ, Parenti F. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria. J Antimicrob Chemother. 1988; 21 Suppl A: 61-67
15. Reed MD, Yamashita TS, Myers CM, Blumer JL. The pharmacokinetics of teicoplanin in infants and children. J Antimicrob Chemother. 1997; 39: 789-796.
16. Sudina GF, Mirzoeva OK, Pushkareva MA, Korshunova GA, Sumbatyan NV, Varfolomeev SD. Caffeic acid phenethyl ester as alipoxygenase inhibitor with antioxidant properties. FEBS Letters 1993; 329: 21-24.
17. Russo A, Longo R, Vanella A. Antioxidant activity of propolis: role of caffeic acid phenethyl ester and galangin. Fitoterapia Supp.1 2002; 73: 21-29.
18. Rossi A, Longo R, Russo A, Borrelli F, Sautebin L. The role of the phenethyl ester of caffeic acid (CAPE) in the inhibition of rat lung cyclooxygenase activity by propolis. Fitoterapia 2002; 73: 30-37.
19. Fadillioglu E, Oztas E, Erdogan H, et al. Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J Appl Toxicol 2004; 24: 47-52.
20. Ozeren M, Sucu N, Tamer L, et al. Caffeic acid phenethyl ester (CAPE) supplemented St. Thomas' hospital cardioplegic solution improves the antioxidant defense system of rat myocardium during ischemia-reperfusion injury. Pharm Res. 2005; 52: 258-63.
21. Irmak MK, Fadillioglu E, Sogut S, et al. Effects of caffeic acid phenethyl ester and alpha-tocopherol on reperfusion injury in rat brain. Cell Biochem Funct. 2003; 21: 283-9.
22. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000; 44: 1247-1254.
23. Ersoz G, Oztuna V, Coskun B, Eskandari MM, Bayarslan C, Kaya A. Addition of fusidic acid impregnated bone cement to systemic teicoplanin therapy in the treatment of rat osteomyelitis. J Chemother 2004; 16: 51-55.
24. Gracia E, Lacleriga A, Monzon M, Leiva J, Oteiza C, Amorena B. Application of a rat osteomyelitis model to compare in vivo and in vitro the antibiotic efficacy against bacteria with high capacity to form biofilms. J Surg Res. 1998; 79: 146-53.
25. Baron EJ, Peterson LR, Finegold SM. Bailey and Scott's Diagnostic Microbiology, 9th ed. St. Louis, Mosby, 1994; 284-295.
26. Yagi K. Lipid peroxides and related radicals in clinical medicine. In Free radicals in diagnostic medicine, Armstrong D (ed). Plenum Press: New York, 1994; 1-15.
27. rd edn) JB Lippincott: New York and Philadelphia, 1996: 765-777.
28. Golowich SP, Kaplan SD: Methods in enzymology, Aca. Press Inc, vol II, New York, 1955:769.
29. Koltuksuz U, Irmak MK, Karaman A, et al. Testicular nitric oxide levels after unilateral testicular torsion/detorsion in rats pretreated with caffeic acid phenethyl ester. Urol Res. 2000; 28: 360-363.
30. Vital statistics and miscellaneous information. In: Experimental and surgical technique in the rat. Ed: Waynforth HB and Flecknell PA. Second edition 1994 American Press Limited. San Diego, CA p;341-367.
31. Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Outcomes related to vancomycin resistant Entercoccus and methicillin resistant Staphylococcus aureus; a comparison of two types of control groups [abstract 111] In: Program and abstracts of the 42nd Interscience conference on Antimicrobial agents and Chemotherapy (San Diego) Washington DC: American Society of Microbiology 2002.
32. Milano CA, Kesler K, Archibald N, Sexton DJ, Jones RH. Mediastinitis after coronary artery bypass surgery. Risk factors and survival. Circulation 1995; 92: 2245-2251.
33. Friedland JS. Chemokines and human infection. Clin Sci 1995; 88: 393-400.
34. Tsuneyoshi I, Kanmura Y, Yoshimura N. Lipoteichoic acid from Staphylococcus aureus depresses contractile function of human arteries in vitro due to the induction of nitric oxide synthase. Anesth Analg. 1996; 82: 948-953.
35. Hattor Y, Kasai K, Akimoto K, Thiemermann C. Induction of NO synthesis by lipoteichoic acid from Staphylococcus aureus in J774 macrophages: involvement of a CD14-dependent pathway. Biochem Biophys Res Commun 1997; 233: 375-379
36. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
37. Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother. 1995; 39: 1842-1847.
38. Schaad HJ, Chuard C, Vaudaux P, Waldvogel FA, Lew DP. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1994; 38: 1703-1710.
39. Wilson AP, Gruneberg RN. Use of teicoplanin in community medicine. Eur J Clin Microbiol Infect Dis. 1994; 13: 701-710.
40. Wilson AP, Gruneberg RN, Neu H. Dosage recommendations for teicoplanin. J Antimicrob Chemother. 1993; 32: 792-796.
41. Martin C, Bourget P, Alaya M, et al. Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Antimicrob Agents Chemother. 1997; 41: 1150-1155.
42. Miglioli PA, Merlo F, Fabbri A, Padrini R. Teicoplanin concentrations in serum, pericardium, pericardial fluid and thoracic wall fat in patients undergoing cardio-pulmonary bypass surgery. J Antimicrob Chemother. 1997; 39: 229-233.
43. Miglioli PA, Merlo F, Campanile F, Padrini R. Effects of cardiopulmonary bypass on teicoplanin serum disposition. Int J Clin Pharmacol Res. 1995; 15: 23-25.
44. Bhakdi S, Klonisch T, Nuber P, Fischer W. Stimulation of monokine production by lipoteichoic acids. Infect Immun 1991; 59: 4614-4620.
45. Keller R, Fischer W, Keist R, Bassetti S. Macrophage response to bacteria: Induction of marked secretory and cellular activities by lipoteichoic acids. Infect Immun 1992; 60: 3664-3672.
46. Garden DL, Granger N. Pathophysiology of ischemia-reperfusion injury. J Pathol 2000; 190: 255-266.
47. Seekamp A, Ward PA. Ischemia-reperfusion injury. Agents Actions 1993; 41 Suppl: 137-152.